Analysis and verification of the HMGB1 signaling pathway
 Haijun Gong^{1}Email author,
 Paolo Zuliani^{1}Email author,
 Anvesh Komuravelli^{1},
 James R Faeder^{2} and
 Edmund M Clarke^{1}
https://doi.org/10.1186/1471210511S7S10
© Gong etal; licensee BioMed Central Ltd. 2010
Published: 15 October 2010
Abstract
Background
Recent studies have found that overexpression of the Highmobility group box1 (HMGB1) protein, in conjunction with its receptors for advanced glycation end products (RAGEs) and tolllike receptors (TLRs), is associated with proliferation of various cancer types, including that of the breast and pancreatic.
Results
We have developed a rulebased model of crosstalk between the HMGB1 signaling pathway and other key cancer signaling pathways. The model has been simulated using both ordinary differential equations (ODEs) and discrete stochastic simulation. We have applied an automated verification technique, Statistical Model Checking, to validate interesting temporal properties of our model.
Conclusions
Our simulations show that, if HMGB1 is overexpressed, then the oncoproteins CyclinD/E, which regulate cell proliferation, are overexpressed, while tumor suppressor proteins that regulate cell apoptosis (programmed cell death), such as p53, are repressed. Discrete, stochastic simulations show that p53 and MDM2 oscillations continue even after 10 hours, as observed by experiments. This property is not exhibited by the deterministic ODE simulation, for the chosen parameters. Moreover, the models also predict that mutations of RAS, ARF and P21 in the context of HMGB1 signaling can influence the cancer cell's fate  apoptosis or survival  through the crosstalk of different pathways.
Keywords
Background
The cell cycle is strictly regulated and controlled by a complex network of signaling pathways [1], comprised of hundreds of proteins. If some important proteins are mutated or there are defects in the signaling mechanisms, normal cell growth regulation will break down, possibly leading to the occurrence of cancer in the future. Moreover, a number of extracellular proteins can bind to their receptors and activate signaling pathways that promote the proliferation of cancer cells.
The highmobility group box1 (HMGB1) protein is a DNAbinding nuclear protein, released actively in response to cytokine stimulation, or passively during cell death [2], and it is present in almost all eukaryotic cells [3–6]. HMGB1 can activate a series of signaling components, including mitogenactivated protein kinases (MAPKs) and AKT, which play an important role in tumor growth and inflammation, through binding to different surface receptors, such as RAGE and TLR2/4. Several studies have shown that elevated expression of HMGB1 occurs in many tumors [7–10] and accelerates cellcycle progression. Recent in vitro studies with pancreatic cancer cells [11] revealed that the targeted knockout or inhibition of HMGB1 and RAGE could increase apoptosis and suppress pancreatic cancer cell growth. This phenomenon has been also observed with lung cancer and other types of cancer cells [8, 12].
The HMGB1 signal transduction can influence the cell's fate by two important processes  apoptosis and cell proliferation  which are regulated respectively by the proteins p53 and CyclinE, acting in two different signaling pathways. The protein p53 is one of the most important tumor suppressor proteins: its activation can lead to cell cycle arrest, DNA repair, or apoptosis. Mutations of p53 occur at a frequency of 50% or higher in many different cancer types [13]. CyclinE is a cell cycle regulatory protein which regulates the G1S phase transition during cell proliferation. Cancer cells often exhibit high expression levels of CyclinE and aberrant CyclinE activity [14]. Many studies have found evidence of crosstalk between the two signaling pathways involving p53 and CyclinE [15]. The crosstalk is regulated by tumor suppressor proteins, including ARF, P21 and FBXW7, which are also frequently mutated in many cancers. In this paper, we ask the following questions: How do these proteins and their mutations change the cell's fate  apoptosis or survival  when HMGB1 signal transduction is activated? Which signaling pathways are fundamental for describing HMGB1 signal transduction, and what mechanisms are responsible to explain recent results linking overexpression of HMGB1 with decrease of apoptosis (and increased cancer cell survival)?
To the best of the authors' knowledge, no computational model has been proposed to investigate the importance of HMGB1 in tumor proliferation. In this work, we construct a simple model of HMGB1 signal transduction to investigate tumorigenesis on the basis of known signaling pathway studies [16–21]. We also constructed a crosstalk network between these known pathways based on hypothetical mechanisms suggested by recent experiments. The HMGB1 pathway is not well understood at the mechanistic level, so our model can provide some insights into the study of HMGB1's roles in tumor proliferation. A series of deterministic and stochastic simulation experiments was conducted to investigate the properties of the HMGB1 pathway.
Finally, we analyze our pathway model against interesting behavorial properties by means of Model Checking techniques. Model Checking is an automated verification technique for hardware and software systems [22]. Recently, there has been growing interest in formal verification of stochastic systems, and, which has recently seen a growing number of applications to biological systems [23–25], by means of Model Checking techniques. The Methods section introduces statistical model checking, which we then apply to validate our pathway model against experimental results from the literature.
Methods
HMGB1 signaling pathway
The p53MDM2 pathway is regulated by a negative feedback loop [26]: PI3K → PIP3 → AKT → MDM2 ⊣ p53 → MDM2, and a positive feedback loop: p53 → PTEN ⊣ PIP3 → AKT → MDM2 ⊣ p53. The protein PI3K is activated by the tolllike receptors (TLR2/4) within several minutes after TLR2/4 activation by HMGB1 [27]. In turn, PI3K phosphorylates the phosphatidylinositol 4,5bisphosphate (PIP2) to phosphatidylinositol (3,4,5)trisphosphate (PIP3), leading to phosphorylation of AKT. The unphosphorylated oncoprotein MDM2, which is one of p53's transcription targets [28], resides in the cytoplasm, and cannot enter the nucleus until it is phosphorylated by activated AKT. The phosphorylated MDM2 translocates into the nucleus to bind with p53, inhibiting p53's transcription activity and initializing p53 polyubiquitination [29], which targets it for degradation. Also, p53 can regulate the transcription of PTEN [30], a tumor suppressor protein, which can hydrolyze PIP3 to PIP2, thereby inhibiting the activation of AKT and MDM2.
The RASERK pathway is the activation sequence: RAS → RAF → MEK → ERK → CyclinD. Activation of RAGE by HMGB1 leads to RAS activation, which in turn activates its effector protein RAF. Activated RAF will phosphorylate the MEK proteins (mitogenactivated protein kinase kinases (MAPKK)), leading to the phosphorylation of ERK1/2 (also called MAPKs). Activated ERK can phosphorylate some transcription factors which activate the expression of the regulatory protein CyclinD and Myc, enabling progression of the cell cycle through the G1 phase. KRAS, a member of the RAS protein family, is found to be mutated in over 90% of pancreatic cancers [31].
The RbE2F pathway is composed of the interactions: CyclinD ⊣ Rb ⊣ E2F → CyclinE ⊣ Rb. The RbE2F pathway regulates the G1S phase transition in the cell cycle during cell proliferation. E2F is a transcription factor that can activate the transcription of many proteins involved in DNA replication and cellcycle progression [32]. In quiescent cells, E2F is bound by unphosphorylated Rb  a tumor suppressor protein  forming an RbE2F complex which inhibits E2F's transcription activity. E2F will be activated and released when its inhibitor Rb is phosphorylated by some oncoproteins (CyclinD and Myc in Fig. 1), leading to the transcription of CyclinE and Cyclindependent protein kinase 2 (CDK2) which promote cellcycle progression. CyclinE, in turn, continues to inhibit the activity of Rb, leading to a positive feedback loop [33–35]. Fig. 1 shows that the activity of CyclinDCDK4/6 (only CyclinD is shown in Fig. 1) is inhibited by the tumor suppressor protein INK4A, which is inactivated in up to 90% pancreatic cancers [36].
The crosstalk between these pathways can influence the cell's fate since the three signaling pathways in HMGB1 signal transduction are not independent. As shown in Fig. 1, the oncoprotein RAS can also activate the PI3KAKT signaling pathway; the tumor suppressor ARF protein induced by E2F can bind to MDM2 to promote its rapid degradation and stabilize p53. Furthermore, it has been experimentally observed [13] that the p53dependent tumor suppressor proteins P21 and FBXW7 can inhibit the activity of cyclin dependent kinases (In Fig. 1, we use P21 to represent both P21 and FBXW7's contribution). Mutations of RAS, ARF, P21 and FBXW7 have been found in many cancers [31, 36, 37]. One of our aims is to investigate how these mutations might influence the cell's fate.
In the HMGB1 model, all substrates are expressed in the number of molecules; proteins with the subscript "a" or "p" correspond respectively to active or phosphorylated forms of the proteins. For example,

RAGE (RAGE_{ a })  inactive (active) form of HMGB1's receptor

MDM2 (MDM2_{ p })  unphosphorylated (phosphorylated) MDM2.
We denote the mRNA transcript of MDM2 by mdm 2. We assume that the total number of active and inactive forms of the RAGE, PI3K, PIP, AKT, RAS, RAF, MEK, and ERK molecules is constant. For example, AKT + AKT_{ p } = AKT_{ tot }, PIP2 + PIP3 = PIP_{ tot }. We sometimes use CD to stand for the CyclinDCDK4/6 complex, CE for CyclinE, and RE for the RbE2F complex.
The p53MDM2 and RASERK pathways have been studied individually using deterministic ODE methods [16–19, 32]. We instead formulated a reaction model corresponding to the reactions illustrated in Fig. 1 in the form of rules specified in the BioNetGen language [38]. We used Hill functions to describe the rate laws governing protein synthesis, including PTEN, MDM2, CyclinD (CD), Myc, E2F and CyclinE (CE). Our choice was motivated by several studies [19, 39–41], which showed that transcription rates of these proteins are sigmoidal functions of transcription factor (TF) concentrations with positive cooperative Hill coefficients. We used mass action rules for other types of chemical reactions. Both ODEs and Gillespie's stochastic simulation algorithm (SSA) [42] are used to simulate the model with BioNetGen [38]. Stochastic simulation is important because when the number of molecules involved in the reactions is small, stochasticity and discretization effects become more prominent [43–45]. In the online Additional file 1, we list 23 ordinary differential equations which describe the deterministic HMGB1 model and all the input parameters. The BioNetGen code which implements SSA and ODE models is available at [46].
Since our understanding of many chemical reactions at the mechanistic level is not clear, a large number of parameters involved in these reactions are difficult to estimate based on existing data. We emphasize that in our HMGB1 model the values for some undetermined parameters were chosen in order to produce a qualitative agreement with previous experiments.
Model Checking
Model Checking [22, 47] is one of the leading techniques for the automated verification and analysis of hardware and software systems. Given a highlevel behavior specification, a model checker verifies whether a system (or model) satisfies it. A specification might be satisfied by many different models. Thus, model checking is the process of determining whether or not a given system model satisfies (is a model of) a property describing the desired behavior of the system. Mathematically, system models take the form of statetransition diagrams, while some version of temporal logic [48] is used to describe the desired properties (specifications) of system executions. A typical property stated in temporal logic is G(grant_req→ F ack), meaning that it is always (G = globally) true that a grant request eventually (F = future) triggers an acknowledgment. One important aspect of Model Checking is that it can be performed algorithmically  user intervention is limited to providing a system model and a property to check.
The Probabilistic Model Checking problem (PMC) is to decide whether a stochastic model satisfies a temporal logic property with a probability greater than or equal to a certain threshold. To express temporal properties, we use a logic in which the temporal operators are equipped with bounds. For example, the property "CyclinD will always stay below 10 in the next fifty time units " is written as G^{50}(CyclinD < 10). We now ask whether our stochastic system M satisfies that formula with a probability greater than or equal to a fixed threshold (say 0.9), and we write M = Pr_{≥ 0.9}[G^{50}(CyclinD < 10)]. In the next section, we formally define the temporal logic used in this work, Bounded Linear Temporal Logic [23].
Bounded Linear Temporal Logic (BLTL)
The bounded until operator ϕ_{1} U^{ t } ϕ_{2} requires that, within time t, ϕ_{2} will be true and ϕ_{1} will hold until then. Bounded versions of the F and G operators can be easily defined: F^{ t } ϕ = true U ^{t} ϕ requires ϕ to hold true within time t;G^{ t } ϕ = ¬F^{ t } ¬ ϕ requires ϕ to hold true up to time t.
The semantics of BLTL is defined with respect to traces (or executions) of a system. In our case, a trace will be the output of a simulation of a BioNetGen stochastic model. Formally, a trace is a sequence of timestamped state transitions of the form σ = (s_{0},t_{0}), (s_{1},t_{1}),..., which means that the system moved to state s_{i+1}after having sojourned for time t_{ i }in state s_{ i }. The fact that a trace σ satisfies the BLTL property ϕ is written as σ = ϕ. We denote the trace suffix starting at step k by σ^{ k }. We have the following semantics of BLTL:

σ^{ k }⊨ AP if and only if AP holds true in state s_{ k };

σ^{ k }⊨ ϕ_{1} ∧ ϕ_{2} if and only if σ^{ k }⊨ ϕ_{1} and σ^{ k }⊨ ϕ_{2};

σ^{ k }⊨ ϕ_{1} ∨ ϕ_{2} if and only if σ^{ k }⊨ ϕ_{1} or σ^{ k }⊨ ϕ_{2};

σ^{ k }⊨ ¬ϕ_{1} if and only if σ^{ k }⊨ ϕ_{1} does not hold;

σ^{ k }⊨ ϕ_{1}U^{ t }ϕ_{2} if and only if there exists i ∈ N such that, (a)∑_{0 ≤ l <i}t_{k+l}≤ t, (b) σ^{k+i}⊨ ϕ_{2} and (c) for each 0 ≤ j <i, σ^{k+j}⊨ ϕ_{1}.
The semantics of BLTL are defined over infinite traces, but it can be shown that traces of an appropriate (finite) length are sufficient to decide BLTL properties [49].
Statistical Model Checking
We briefly explain Statistical Model Checking [50, 51], the technique we use for verifying BioNetGen models simulated by Gillespie's algorithm. Statistical Model Checking treats the Probabilistic Model Checking problem as a statistical inference problem, and solves it by randomized sampling of the traces (simulations) from the model. In particular, the PMC problem is naturally phrased as a hypothesis testing problem, i.e., deciding between two hypotheses  M ⊨ Pr_{≥θ}[ϕ] versus M ⊨ Pr_{ < θ }[ϕ]. In other words, to determine whether a stochastic system M satisfies ϕ with a probability p ≥ θ, we test the hypothesis H_{0} : p ≥ θ against H_{1} : p < θ. Sampled traces are model checked individually to determine whether a given property ϕ holds, and the number of satisfying traces is used by a hypothesis testing procedure to decide between H_{0} and H_{1}. Note that Statistical Model Checking cannot guarantee a correct answer to the PMC problem. However, the probability of giving a wrong answer can be made arbitrarily small.
We have introduced a Bayesian sequential hypothesis testing approach and applied it to the verification of rulebased models of signaling pathways and other stochastic systems [23, 49]. Sequential sampling means that the number of sampled traces is not fixed a priori, but is instead determined at "runtime ", depending on the evidence gathered by the samples seen so far. This often leads to a significantly smaller number of sampled traces.
Therefore, by running a system simulation (i.e., a BioNetGen stochastic simulation) and by checking ϕ on the resulting trace we can obtain a sample from random variable X. When a sample of X evaluates to 1 we call it a success, otherwise, a failure.
The Bayesian approach assumes that p is given by a random variable whose distribution is called the prior distribution. The prior is usually based on our previous experiences and knowledge about the system.
The following Proposition shows that, in our special case of Bernoulli samples, the computation of the Bayes Factor is straightforward.
where $x={\displaystyle {\sum}_{i=1}^{n}{x}_{i}}$ is the number of successes in(x_{1},..., x_{ n }) and F_{(s,t)}(·) is the Beta distribution function of parameters s, t.
The Beta distribution function can be efficiently computed by standard software packages. Thus, no numerical integration is required for the evaluation of the Bayes Factor.
Finally, we must show that the error probability of our decision procedure, i.e., the probability that we reject (accept) the null hypothesis although it is true (false), can be bounded.
Theorem. [49]The error probability for the sequential Bayesian hypothesis testing algorithm is bounded above by $\frac{1}{T}$where T is the Bayes Factor threshold given as input.
Results and discussion
We first conducted a series of deterministic and stochastic simulation experiments to study the properties of our HMGB1 signaling pathway model. Then, we applied the statistical model checking technique to validate some important temporal properties of our HMGB1 model.
Simulation results
Initial values for the model
RAGE  PI 3K  PIP 2  AKT  MDM 2  MDM 2_{ p }  P 53  RAS  RAF  MEK  ERK  RE 

10^{3}  10^{5}  10^{5}  10^{5}  10^{4}  2 × 10^{4}  2 × 10^{4}  10^{4}  10^{4}  10^{4}  10^{4}  10^{5} 
Fig. 4(B, E) shows that the cell cycle regulatory proteins CyclinD/E will increase with the elevated expression of HMGB1, a behavior which could be verified by future experiments. Fig. 4(AB, DE) explains the experimental discovery that the overexpression of HMGB1 decreases apoptosis and promotes DNA replication and proliferation in cancer cells.
The oncoprotein AKT is overexpressed in many cancers [54]. In Fig. 4(C, F), we first increase the number of unphosphorylated AKT molecules and fix the other proteins' concentration, then measure p53 and MDM2_{ p } 's expression levels at 10 hours in phase G1 after HMGB1 activates its receptor RAGE. Fig. 4(C, F) shows that with the increase of AKT's expression level, p53 is repressed due to the ubiquitination initiated by the overexpressed MDM2_{ p }, which is promoted by the activated and overexpressed AKT protein. The results in Fig. 4(C, F) suggest a way to inhibit tumor cell proliferation and induce tumor cell apoptosis through the inhibition of protein phosporylation events downstream from AKT kinases in the PI3K/AKT pathway, using an AKT kinase inhibitor (such as the drug GSK690693 [55]).
KRAS is a member of the RAS protein family. KRAS mutation and ARF loss occur in more than 80% of pancreatic cancers [36, 53]. The P21 and FBXW7 proteins are also frequently mutated in many cancers [37]. ARF and P21 play an important role in the crosstalk between the p53 and Rb pathways. ARF is able to reroute cells with oncogenic damage to p53dependent fates through binding to MDM2 and targeting its degradation. The p53dependent tumor suppressor proteins P21 and FBXW7 can inhibit CyclinD/E's activity to prevent the proliferation of cancer cells.
Fig. 5(A, D) shows that wildtype ARF (large d_{ ARF } ) can decrease the number of MDM2_{ p } molecules and increase p53's expression level to initiate apoptosis even if the cell proceeds to the S phase. Moreover, mutated ARF (smaller d_{ ARF } ) can not stabilize p53 expression and prevent the proliferation of cancer cells if HMGB1 is overexpressed. This could explain the phenomenon that ARF loss exists in over 80% of pancreatic cancers [36]. Fig. 5(B, E) demonstrates that CyclinD/E proteins will increase if P21 is mutated (smaller d_{P 21}), thereby accelerating cell cycle progression.
KRAS is mutated in most cancers, especially in pancreatic cancer [31]. The activation of RAS is initiated by HMGB1 and its receptors, and the wildtype RAS can be deactivated by some kinases. Studies have found that the mutated KRAS can not be deactivated [56], even if HMGB1 is knocked out, so it will continuously activate the downstream signaling pathways which promote cell proliferation. Fig. 5(C, F) shows that with the increase of RAS deactivation rate d_{ RAS } (b_{1} in the ODE model), the synthesis of CyclinD/E will be inhibited, but a small deactivation rate of RAS will lead to overexpression of CyclinD/E. The results visualized in Fig. 5 suggest some ways to inhibit cancer cell proliferation through inhibition or deactivation of the signaling pathways involving RAS, Cyclin, and Cyclindependent kinases (CDK). Recently, CDK and RAS inhibitor drugs [57–59] have been developed to inhibit tumor growth.
Verification of the HMGB1 model
We use Statistical Model Checking (SMC) to verify some fundamental properties that our model should satisfy. We test whether the model satisfies a given BLTL property with probability p ≥ 0.9. We set the threshold T = 1000 for the verification, so the probability of a wrong answer is smaller than 10^{3}.
Verification of property 1
Property 1: Pr_{≥ 0.9}[F^{ t }(G^{900}(P 53 < 3.3 × 10^{4}))]  

t (min)  # of Samples  # of Successes  Result  Time (s) 
400  53  49  True  597.59 
500  23  22  True  271.76 
600  22  22  True  263.79 
that is, within 100 minutes p53's level will eventually be larger than 5.3 × 10^{4}. SMC accepts this property as true, after sampling 38 traces (of which 37 satisfying traces).
Verification of property 3
Property 3: Pr_{≥ 0.9}[F^{20}(PI 3K_{a}/PI 3K_{tot} > 0.5)]  

HMGB1  # of Samples  # of Successes  Result  Time (s) 
10^{3}  9  0  False  6.49 
9 × 10^{3}  380  315  False  285.16 
10^{5}  22  22  True  16.39 
Verification of property 4 and 5
Property 4: Pr_{≥ 0.9}[F^{600}(CyclinE> 900)]  Property 5: Pr_{≥ 0.9}[F^{600}(CyclinD> 900)]  

HMGB1  # of Samples  # of Success  Result  dRAS  # of Samples  # of Success  Result 
10^{2}  9  0  False  10^{6}  22  22  True 
10^{3}  55  16  False  10^{2}  26  5  False 
10^{6}  22  22  True  10^{1}  9  0  False 
with different RAS deactivation rates (d_{ RAS }). The results are presented in Table 4. Properties 4 and 5 show that the overexpression of HMGB1 and mutation of RAS (small d_{ RAS } value) will accelerate the expression of cell regulatory protein CyclinD/E to promote cell proliferation. However, inhibition of HMGB1 and an increase of RAS deactivation rate will prevent tumor growth.
SMC accepted this property as true (22 satisfying traces).
Verification of property 7
Property 7: Pr_{≥ 0.9}[F^{100}(P 53/10000 ≥ a∧ F^{100}(P 53/10000 ≤ 0.4))]  

HMGB1  a  # of Samples  # of Successes  Result  Time (s) 
10^{3}  5.0  22  22  True  19.74 
10^{3}  5.5  20  3  False  29.02 
10^{2}  5.5  22  22  True  19.65 
10^{2}  6.0  45  12  False  56.27 
10  6.5  38  37  True  41.50 
Conclusions
We have presented a reaction network model of the signaling transduction initiated by HMGB1. The model incorporates the contributions from the most important known signaling components of the HMGB1 signal transduction network. The model is expressed in the form of BioNetGen rules, and simulated using ODEs and Gillespie's algorithm under a range of conditions. We used Statistical Model Checking to automatically validate our model with respect to known experimental results.
Our simulations demonstrate a dosedependent p53 and CyclinE response curve to increasing HMGB1 stimulus. This hypothesis could be tested by future experiments. In particular, overexpression of HMGB1 promotes the cell cycle regulatory proteins E2F and CyclinD/E and inhibits the proapoptotic protein p53, leading to increased cancer cell survival and decreased apoptosis. This is consistent with experimental observations in recent studies of cancer cells [11]. We also investigated the roles of different components in the pathway and predicted their activity in response to various conditions. We investigated how mutations of the RAS, ARF and P21 proteins influence the fate of the cancer cell. In particular, parameter variation showed that the mutated RAS increases the expression level of CyclinE, leading to cancer cell proliferation. Mutation or loss of the ARF protein leads to high MDM2 activity and loss of p53 expression in the face of HMGB1 overexpression, resulting in decreased apoptosis. Our model shows that the inhibition (or deactivation) of RAS, Cyclin, and Cyclindependent kinases (CDK) might inhibit tumor growth.
Since our proposed model is based on just three signaling pathways, we are far from capturing the entire HMGB1 network dynamics. Studies have found that HMGB1 can not only activate the PI3KAKT and RASERK pathways, but can also activate the NFκ B signaling pathway [27], which regulates many proapoptotic and antiapoptotic proteins' transcription [60]. Since HMGB1 could be released passively during necrosis, there might exist crosstalk between the tumor necrosis factor (TNF) pathway and the HMGB1 pathway. Besides the incorporation of new pathways, recent work has demonstrated that HMGB1 can bind to p53 directly to influence p53mediated transcriptional activity [61]. A larger network for HMGB1 signal transduction will be explored in our future work.
It has been recently observed that pancreatic tumor cells increase autophagy [11] and release HMGB1 [10] in response to chemotherapy, radiation, and hypoxia, which may promote tumor cell survival. It has been hypothesized that direct inhibition of autophagy may be another way to inhibit tumor growth and enhance the efficacy of cancer therapies [11]. The incorporation of autophagic proteins into the HMGB1 signaling pathway is worth considering in future work.
Although our current model can only qualitatively compare with the experimental behavior, it still provides valuable information about the behavior of HMGB1 signal transduction in response to different stimuli. Future experiments will enable the development of more realistic models. We anticipate that the application of model checking techniques, such as those explored in this work, will facilitate the development of targeted and effective anticancer therapies.
Declarations
Acknowledgements
This work was supported by a grant from the U.S. National Science Foundation's Expeditions in Computing Program (award ID 0926181). The authors thank Michael T. Lotze (University of Pittsburgh) for calling their attention to HMGB1 and for helpful discussions of the topic. H.G. would like to thank Marco E. Bianchi (San Raffaele University) for email discussions on HMGB1. We would also like to thank Ilya Korsunsky and Màtè L. Nagy for their comments on this paper.
This article has been published as part of BMC Bioinformatics Volume 11 Supplement 7, 2010: Ninth International Conference on Bioinformatics (InCoB2010): Bioinformatics. The full contents of the supplement are available online at http://www.biomedcentral.com/14712105/11?issue=S7.
Authors’ Affiliations
References
 Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100: 57–70. 10.1016/S00928674(00)816839View ArticlePubMedGoogle Scholar
 Scaffidi P, Misteli T, Bianchi M: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418: 191–195. 10.1038/nature00858View ArticlePubMedGoogle Scholar
 Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A, Rubartelli A: Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 2003, 22: 5551–5560. 10.1093/emboj/cdg516PubMed CentralView ArticlePubMedGoogle Scholar
 Wang H, Bloom O, Zhang M, Vishnubhakat J, Ombrellino M, Frazier A, Yang H: HMG1 as a late mediator of endotoxin lethality in mice. Science 1999, 285: 248. 10.1126/science.285.5425.248View ArticlePubMedGoogle Scholar
 Dumitriu IE, Baruah P, Valentinis B, et al.: Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. The Journal of Immunology 2005, 174: 7506–7515.View ArticlePubMedGoogle Scholar
 Semino C, Angelini G, Poggi A, Rubartelli A: NK/iDC interaction results in IL18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood 2005, 106: 609–616. 10.1182/blood2004103906View ArticlePubMedGoogle Scholar
 Sparvero L, AsafuAdje D, Kang R, Tang D, Amin N, et al.: RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. Journal of Translational Medicine 2009, 7: 17. 10.1186/14795876717PubMed CentralView ArticlePubMedGoogle Scholar
 Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, et al.: Masquerader: high mobility group box1 and cancer. Clinical Cancer Research 2007, 13: 2836–2848. 10.1158/10780432.CCR061953View ArticlePubMedGoogle Scholar
 Lotze MT, Tracey K: Highmobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nature Reviews Immunology 2005, 5: 331–342. 10.1038/nri1594View ArticlePubMedGoogle Scholar
 Vakkila J, Lotze MT: Inflammation and necrosis promote tumour growth. Nature Reviews Immunology 2004, 4: 641–648. 10.1038/nri1415View ArticlePubMedGoogle Scholar
 Kang R, Tang D, Schapiro NE, Livesey KM, Farkas A, Loughran P, Lotze MT, Zeh HJ: The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ 2010, 17(4):666–676. 10.1038/cdd.2009.149PubMed CentralView ArticlePubMedGoogle Scholar
 Brezniceanu ML, Volp K, Bosser S, Solbach C, Lichter P, et al.: HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB Journal 2003, 17: 1295–1297.PubMedGoogle Scholar
 Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature 2000, 408: 307–310. 10.1038/35042675View ArticlePubMedGoogle Scholar
 Minella AC, Grim JE, Welcker M, Clurman BE: p53 and SCFFbw7 cooperatively restrain cyclin Eassociated genome instability. Oncogene 2007, 26: 6948–6953. 10.1038/sj.onc.1210518View ArticlePubMedGoogle Scholar
 Pestov DG, Strezoska A, Lau LF: Evidence of p53dependent crosstalk between ribosome biogenesis and the cell cycle: effects of nucleolar protein Bop1 on G1/S transition. Molecular and Cellular Biology 2001, 21(13):4246–4255. 10.1128/MCB.21.13.42464255.2001PubMed CentralView ArticlePubMedGoogle Scholar
 Wee KB, Aguda BD: Akt versus p53 in a network of oncogenes and tumor suppressor genes regulating cell survival and death. Biophysical Journal 2006, 91: 857–865. 10.1529/biophysj.105.077693PubMed CentralView ArticlePubMedGoogle Scholar
 Wee KB, Surana U, Aguda BD: Oscillations of the p53Akt Network: Implications on Cell Survival and Death. PloS One 2009, 4: e4407. 10.1371/journal.pone.0004407PubMed CentralView ArticlePubMedGoogle Scholar
 Ciliberto A, Novak B, Tyson J: Steady States and Oscillations in the p53/Mdm2 Network. Cell Cycle 2005, 4(3):488–493.View ArticlePubMedGoogle Scholar
 Zhang T, Brazhnik P, Tyson J: Exploring mechanisms of the DNAdamage response: p53 pulses and their possible relevance to apoptosis. Cell Cycle 2007, 6: 85e10. 10.4161/cc.6.16.4577View ArticlePubMedGoogle Scholar
 Puszynski K, Hat B, Lipniacki T: Oscillations and bistability in the stochastic model of p53 regulation. Journal of Theoretical Biology 2008, 254: 452–465. 10.1016/j.jtbi.2008.05.039View ArticlePubMedGoogle Scholar
 Bottani S, Grammaticos B: Analysis of a minimal model for p53 oscillations. Journal of Theoretical Biology 2007, 249: 235–245. 10.1016/j.jtbi.2007.04.026View ArticlePubMedGoogle Scholar
 Clarke EM, Grumberg O, Peled DA: Model Checking. MIT Press; 1999.Google Scholar
 Jha SK, Clarke EM, Langmead CJ, Legay A, Platzer A, Zuliani P: A bayesian approach to model checking biological system. CMSB, Volume 5688 of LNCS 2009, 218–234.Google Scholar
 Langmead CJ: Generalized Queries and Bayesian Statistical Model Checking in Dynamic Bayesian Networks: Application to Personalized Medicine. CSB 2009, 201–212.Google Scholar
 Rizk A, Batt G, Fages F, Soliman S: On a continuous degree of satisfaction of temporal logic formulae with applications to systems biology. CMSB, Volume 5307 of LNCS 2008, 251–268.Google Scholar
 Larris S, Levine AJ: The p53 pathway: positive and negative feedback loops. Oncogene 2005, 24: 2899–2908. 10.1038/sj.onc.1208615View ArticleGoogle Scholar
 van Beijnum JR, Buurman WA, Griffioen AW: Convergence and amplification of tolllike receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1. Angiogenesis 2008, 11: 91–99. 10.1007/s1045600890935View ArticlePubMedGoogle Scholar
 Barak Y, Juven T, Haffiner R, Oren M: mdm2 expression is induced by wild type p53 activity. EMBO J 1993, 12: 461–468.PubMed CentralPubMedGoogle Scholar
 Haupt Y, Maya R, Kasaz A, Oren M: Mdm2 promotes the rapid degradation of p53. Nature 1997, 387: 296–299. 10.1038/387296a0View ArticlePubMedGoogle Scholar
 BlancoAparicio C, Renner O, Leal J, Carnero A: PTEN, more than the AKT pathway. Carcinogenesis 2007, 28: 1379–1386. 10.1093/carcin/bgm052View ArticlePubMedGoogle Scholar
 Downward J: Targeting RAS signalling pathways in cancer therapy. Nature Reviews Cancer 2003, 3: 11–22. 10.1038/nrc969View ArticlePubMedGoogle Scholar
 Yao G, Lee TJ, Mori S, Nevins J, You L: A bistable RbE2F switch underlies the restriction point. Nature Cell Biology 2008, 10: 476–482. 10.1038/ncb1711View ArticlePubMedGoogle Scholar
 Sherr CJ, McCormick F: The RB and p53 pathways in cancer. Cancer Cell 2002, 2: 103–112. 10.1016/S15356108(02)001022View ArticlePubMedGoogle Scholar
 Sears R, Nevins J: Signaling networks that link cell proliferation and cell fate. The Journal of Biological Chemistry 2002, 277: 11617–11620. 10.1074/jbc.R100063200View ArticlePubMedGoogle Scholar
 Nevins JR: The Rb/E2F pathway and cancer. Human Molecular Genetics 2001, 10: 699–703. 10.1093/hmg/10.7.699View ArticlePubMedGoogle Scholar
 Bardeesy N, DePinho RA: Pancreatic cancer biology and genetics. Nature Reviews Cancer 2002, 2(12):897–909. 10.1038/nrc949View ArticlePubMedGoogle Scholar
 Mao J, Perezlosada J, Wu D, DelRosario R, Tsunematsu R, Nakayama KI, Brown K, Bryson S, Balmain A: Fbxw7/Cdc4 is a p53dependent, haploinsufficient tumour suppressor gene. Nature 2004, 432: 775–779. 10.1038/nature03155View ArticlePubMedGoogle Scholar
 Hlavacek WS, Faeder JR, Blinov ML, Posner RG, Hucka M, Fontana W: Rules for modeling signaltransduction system. Sci STKE 2006, 2006(344):re6. re6 re6 10.1126/stke.3442006re6PubMedGoogle Scholar
 Bolouri H: Computational Modeling of Gene Regulatory Networks: a primer. Imperial College Press; 2008.View ArticleGoogle Scholar
 Yang H, Hsu C, Hwang M: An Analytical Rate Expression for the Kinetics of Gene Transcription Mediated by Dimeric Transcription Factors. Journal of Biochemistry 2007, 142: 135–144. 10.1093/jb/mvm151View ArticlePubMedGoogle Scholar
 Alon U: An introduction to systems biology: design principles of biological circuits. Chapman & Hall; 2007.Google Scholar
 Gillespie DT: A general method for numerically simulating the stochastic time evolution of coupled chemical reactions. Journal of Computational Physics 1976, 22(4):403–434. 10.1016/00219991(76)900413View ArticleGoogle Scholar
 Gong H, Sengupta H, Linstedt A, Schwartz R: Simulated De Novo Assembly of Golgi Compartments by Selective Cargo Capture during Vesicle Budding and Targeted Vesicle Fusion. Biophysical Journal 2008, 95: 1674–1688. 10.1529/biophysj.107.127498PubMed CentralView ArticlePubMedGoogle Scholar
 Gong H, Guo Y, Linstedt A, Schwartz R: Discrete, continuous, and stochastic models of protein sorting in the Golgi apparatus. Phys Rev E Stat Nonlin Soft Matter Phys 2010, 81: 011914.View ArticlePubMedGoogle Scholar
 Lipniacki T, Hat T, Faeder JR, Hlavacek WS: Stochastic effects and bistability in T cell receptor signaling. Journal of Theoretical Biology 2008, 254: 110–122. 10.1016/j.jtbi.2008.05.001PubMed CentralView ArticlePubMedGoogle Scholar
 HMGB1 BioNetGen Code[http://www.cs.cmu.edu/~haijung/research/HMGB1model.bngl]
 Clarke EM, Emerson EA, Sifakis J: Model checking: algorithmic verification and debugging. Commun ACM 2009, 52(11):74–84. 10.1145/1592761.1592781View ArticleGoogle Scholar
 Pnueli A: The Temporal Logic of Programs. FOCS 1977, 46–57.Google Scholar
 Zuliani P, Platzer A, Clarke EM: Bayesian statistical model checking with application to Simulink/Stateflow verification. HSCC 2010, 243–252. full_textView ArticleGoogle Scholar
 Younes HLS, Simmons RG: Probabilistic Verification of Discrete Event Systems Using Acceptance Sampling. CAV, Volume 2404 of LNCS 2002, 223–235.Google Scholar
 Younes HLS, Simmons RG: Statistical probabilistic model checking with a focus on timebounded properties. Information and Computation 2006, 204(9):1368–1409. 10.1016/j.ic.2006.05.002View ArticleGoogle Scholar
 GevaZatorsky N, Rosenfeld N, Itzkovitz S, Milo R, Sigal A, Dekel E, Yarnitzky T, Liron Y, Polak P, Lahav G, Alon U: Oscillations and variability in the p53 system. Molecular Systems Biology 2006, 2: 2006.0033. 10.1038/msb4100068PubMed CentralView ArticlePubMedGoogle Scholar
 Hahn WC, Weinberg RA: Modelling the molecular circuitry of cance. Nature Reviews Cancer 2002, 2: 331–341. 10.1038/nrc795View ArticlePubMedGoogle Scholar
 Altomare D, Wang H, Skele K, Rienzo AD, KleinSzanto A, Godwin A, Testa J: AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004, 23: 5853–7. 10.1038/sj.onc.1207721View ArticlePubMedGoogle Scholar
 Rhodes N, Heerding D, Duckett D, et al.: Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Research 2008, 68: 2366. 10.1158/00085472.CAN075783View ArticlePubMedGoogle Scholar
 van Krieken J, et al.: KRAS mutation testing for predicting response to antiEGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 2008, 453: 417–431. 10.1007/s004280080665yView ArticlePubMedGoogle Scholar
 McInnes C: Progress in the evaluation of CDK inhibitors as antitumor agents. Drug Discovery Today 2008, 13(1920):875–881. 10.1016/j.drudis.2008.06.012View ArticlePubMedGoogle Scholar
 Malumbres M, Pevarello P, Barbacid M, Bischoff J: CDK inhibitors in cancer therapy: what is next? Trends in Pharmacological Sciences 2008, 29: 16. 10.1016/j.tips.2007.10.012View ArticlePubMedGoogle Scholar
 Rotblat B, Ehrlich M, Haklai R, Kloog Y: The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer. Methods in Enzymology 2008, 439: 467–489. full_textView ArticlePubMedGoogle Scholar
 Lipniacki T, Paszek P, Brasier A, Luxon B, Kimmel M: Crosstalk between p53 and nuclear factorkB systems: proand antiapoptotic functions of NFkB. Journal of Theoretical Biology 2004, 228: 195–215. 10.1016/j.jtbi.2004.01.001View ArticlePubMedGoogle Scholar
 Imamura T, Izumi H, Nagatani G, Ise T, Nomoto M, Iwamoto Y, Kohno K: Interaction with p53 enhances binding of cisplatinmodified DNA by high mobility group 1 protein. J Biol Chem 2001, 276: 7534–7540. 10.1074/jbc.M008143200View ArticlePubMedGoogle Scholar
Copyright
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.